Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002108 · ClinicalTrials.gov registry record · NA
3TC (Lamivudine; GR109714X) Open-Label Program
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002108 is a NA study that has completed, run by Glaxo Wellcome.
The verdict
NCT00002108, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies. To collect data pertaining to the safety of 3TC at two dose levels. To evaluate the effect of 3TC on markers of hepatitis B in co-infected patients at five to ten selected sites.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002108
The ClinicalTrials.gov registry entry for NCT00002108 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zidovudine is the first listed.
NCT00002108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002108 about?
NCT00002108 is a clinical study titled "3TC (Lamivudine; GR109714X) Open-Label Program". To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies. To collect data pertaining to the safety of 3TC at two dose levels. To evaluate the effect of 3...
What is the current status of trial NCT00002108?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002108?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG).
Who is sponsoring clinical trial NCT00002108?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.